Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M

The most recent release (2026-05-27) reports Q1 2026 revenue of US$6.47M, a 29.7% sequential jump from Q4 2025, but a 17.1% year-over-year decline. Gross margin remains high at 91.1%. Operating loss was US$0.786M, widening 261% YoY, though narrowing 14.7% quarter-over-quarter. Crucially, management announced the deferral of the planned U.S. IPO to a later date, while highlighting FDA agreement on a 505(b)(2) path and an animal-health fee waiver.

The context: Innocan spent 2025 and early 2026 preparing for a U.S. listing. On 2026-01-27 it anticipated an NYSE American listing by January 30, 2026, with a concurrent offering. In March and April 2026 it borrowed US$650,000 in secured debentures from its largest shareholder, Tamar Innovest, maturing at the earlier of 12 months or completion of the U.S. IPO. FY2025 (released 2026-03-31) showed US$26.6M revenue (down 9.6% YoY) with similar high margins. The company had telegraphed improving sales trends into Q1 2026, which materialized. However, the IPO was the primary strategic catalyst, and its withdrawal is new, unexpected information.

The Q1 revenue performance is positive but largely in line with the company’s own hints of improving momentum. The IPO deferral, by contrast, is a clear negative surprise. The IPO was intended to fund working capital, cover listing costs, and serve as a liquidity event. Its postponement not only casts doubt on the company’s ability to satisfy the equity story it told for months, but also leaves looming debt maturities without the natural refinancing event the debentures anticipated. While the FDA updates are incremental positives, they do not offset the signal that a near-term U.S. listing is no longer feasible. The combination of ongoing operating losses (US$0.33M in first 9 months of 2025, US$0.79M in Q1 2026 alone) and a removed capital-raising catalyst makes this a material negative development.

Innocan Pharma is a dual-segment company: a pharmaceutical arm developing a liposomal synthetic CBD injection (LPT-CBD) for chronic pain, and a consumer wellness segment operated through its 60%-owned joint venture B.I. Sky Global. The flagship project is LPT-CBD, a once-monthly subcutaneous injection designed to overcome bioavailability and adherence issues of oral CBD. It has shown sustained pain relief and safety in multiple animal models (dogs, goats, minipigs). The FDA has agreed to a 505(b)(2) submission path based on a scientific bridge. The company also holds 31 granted & pending patents across 8 families, with recent allowances in Japan and India. The animal-health indication targets a US$1.07 billion U.S. canine osteoarthritis market and has received an INAD number and a third-year fee waiver from the FDA’s Center for Veterinary Medicine.